表紙：末梢神経障害の世界市場：成長、将来の見通し、競合分析（2022年～2030年）

市場調査レポート

商品コード

1180741

末梢神経障害の世界市場：成長、将来の見通し、競合分析（2022年～2030年）

Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

出版日: 2022年08月24日 | 発行: Acute Market Reports

| ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 4,500 705,420円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 6,500 1,018,940円

レポートPDFを10名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 9,000 1,410,840円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の末梢神経障害市場について調査分析し、市場動向、競合分析、市場力学、セグメント別・地域別の市場分析、企業プロファイルなど、体系的な情報を提供しています。

List of Tables

TABLE 1 Global Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 2 Global Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 3 Global Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 4 Global Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 5 Global Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 6 Global Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 7 North America Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 8 North America Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 9 North America Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 10 North America Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 11 North America Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 12 North America Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 13 U.S. Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 14 U.S. Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 15 U.S. Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 16 U.S. Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 17 U.S. Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 18 U.S. Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 19 Canada Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 20 Canada Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 21 Canada Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 22 Canada Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 23 Canada Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 24 Canada Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 25 Rest of North America Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 26 Rest of North America Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 27 Rest of North America Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 28 Rest of North America Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 29 Rest of North America Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 30 Rest of North America Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 31 UK and European Union Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 32 UK and European Union Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 33 UK and European Union Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 34 UK and European Union Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 35 UK and European Union Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 36 UK and European Union Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 37 UK Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 38 UK Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 39 UK Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 40 UK Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 41 UK Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 42 UK Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 43 Germany Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 44 Germany Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 45 Germany Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 46 Germany Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 47 Germany Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 48 Germany Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 49 Spain Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 50 Spain Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 51 Spain Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 52 Spain Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 53 Spain Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 54 Spain Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 55 Italy Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 56 Italy Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 57 Italy Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 58 Italy Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 59 Italy Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 60 Italy Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 61 France Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 62 France Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 63 France Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 64 France Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 65 France Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 66 France Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 67 Rest of Europe Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 68 Rest of Europe Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 69 Rest of Europe Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 70 Rest of Europe Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 71 Rest of Europe Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 72 Rest of Europe Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 73 Asia Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 74 Asia Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 75 Asia Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 76 Asia Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 77 Asia Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 78 Asia Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 79 China Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 80 China Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 81 China Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 82 China Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 83 China Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 84 China Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 85 Japan Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 86 Japan Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 87 Japan Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 88 Japan Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 89 Japan Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 90 Japan Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 91 India Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 92 India Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 93 India Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 94 India Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 95 India Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 96 India Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 97 Australia Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 98 Australia Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 99 Australia Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 100 Australia Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 101 Australia Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 102 Australia Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 103 South Korea Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 104 South Korea Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 105 South Korea Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 106 South Korea Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 107 South Korea Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 108 South Korea Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 109 Latin America Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 110 Latin America Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 111 Latin America Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 112 Latin America Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 113 Latin America Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 114 Latin America Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 115 Brazil Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 116 Brazil Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 117 Brazil Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 118 Brazil Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 119 Brazil Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 120 Brazil Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 121 Mexico Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 122 Mexico Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 123 Mexico Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 124 Mexico Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 125 Mexico Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 126 Mexico Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 127 Rest of Latin America Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 128 Rest of Latin America Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 129 Rest of Latin America Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 130 Rest of Latin America Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 131 Rest of Latin America Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 132 Rest of Latin America Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 133 Middle East and Africa Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 134 Middle East and Africa Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 135 Middle East and Africa Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 136 Middle East and Africa Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 137 Middle East and Africa Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 138 Middle East and Africa Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 139 GCC Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 140 GCC Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 141 GCC Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 142 GCC Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 143 GCC Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 144 GCC Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 145 Africa Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 146 Africa Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 147 Africa Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 148 Africa Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 149 Africa Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 150 Africa Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 151 Rest of Middle East and Africa Peripheral Neuropathy Market By Treatment Type, 2020-2030, USD (Million)
TABLE 152 Rest of Middle East and Africa Peripheral Neuropathy Market By Pharmacological Therapies, 2020-2030, USD (Million)
TABLE 153 Rest of Middle East and Africa Peripheral Neuropathy Market By Pain Relievers, 2020-2030, USD (Million)
TABLE 154 Rest of Middle East and Africa Peripheral Neuropathy Market By Anti-seizure medicationsction, 2020-2030, USD (Million)
TABLE 155 Rest of Middle East and Africa Peripheral Neuropathy Market By Antidepressants, 2020-2030, USD (Million)
TABLE 156 Rest of Middle East and Africa Peripheral Neuropathy Market By Non-Pharmacological Therapies, 2020-2030, USD (Million)

List of Figures

FIG. 1 Global Peripheral Neuropathy Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Peripheral Neuropathy Market: Quality Assurance
FIG. 5 Global Peripheral Neuropathy Market, By Treatment Type, 2021
FIG. 6 Global Peripheral Neuropathy Market, By Geography, 2021
FIG. 7 Market Geographical Opportunity Matrix - Global Peripheral Neuropathy Market, 2021
FIG. 8 Market Positioning of Key Peripheral Neuropathy Market Players, 2021
FIG. 9 Global Peripheral Neuropathy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
FIG. 10 Global Peripheral Neuropathy Market, By Treatment Type, 2021 Vs 2030, %
FIG. 11 U.S. Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 12 Canada Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 13 Rest of North America Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 14 UK Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 15 Germany Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 16 Spain Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 17 Italy Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 18 France Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 19 Rest of Europe Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 20 China Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 21 Japan Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 22 India Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 23 Australia Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 24 South Korea Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 25 Rest of Asia Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 26 Brazil Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 27 Mexico Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 28 Rest of Latin America Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 29 GCC Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 30 Africa Peripheral Neuropathy Market (US$ Million), 2020 - 2030
FIG. 31 Rest of Middle East and Africa Peripheral Neuropathy Market (US$ Million), 2020 - 2030

Product Code: 137481-08-22

General population studies have reported that 7 to 8% adults currently have chronic neuropathic pain, where the reported incidence is of 8 cases per 1,000 individuals per year. In the U.K. alone, 26% individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030. Anticonvulsant pregabalin (Lyrica, Pfizer) is among the most widely spread drug for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously report cost-benefit to insurers and regulatory bodies. In terms of market competition, the existing brands are being continually expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion

The report titled "Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery).

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global peripheral neuropathy market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global peripheral neuropathy market. This report concludes with company profiles section that highlights major information about the key players engaged in global peripheral neuropathy market. In-depth competitive environment analysis and historical (2021) market size data are also provided in the report.

Pharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizures medications occupies maximum share in peripheral market around 41% in 2016, followed by antidepressants and pain killers. Anti-seizures medication include Gabapentin and Pregabalin, that are used as first line of treatment, with Pregabalin occupying major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.

At present, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high research trials on peripheral neuropathy in the country and high prices of the medication generating high revenue. Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV/AIDS.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Peripheral Neuropathy market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Peripheral Neuropathy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Market Segmentation

Treatment Type

Pharmacological Therapies

Pain Relievers

Tramadol

Oxycodone

Cylcooxgenase Inhibitors

Corticosteroid

Anti-seizure medicationsction

Gabapentin

Pregabalin

Antidepressants

Amitriptyline

Doxepin

Nortriptyline

Duloxetine

Venlafaxine

Non-Pharmacological Therapies

Transcutaneous electrical nerve stimulation

Plasma exchange and intravenous immune globulin

Others(Physical Therapy and Surgery)

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Peripheral Neuropathy market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Peripheral Neuropathy market?

Which is the largest regional market for Peripheral Neuropathy market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Peripheral Neuropathy market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Peripheral Neuropathy market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Peripheral Neuropathy Market
2.2. Global Peripheral Neuropathy Market, By Treatment Type, 2021 (US$ Million)
2.3. Global Peripheral Neuropathy Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021

3. Peripheral Neuropathy Market: Competitive Analysis

3.1. Market Positioning of Key Peripheral Neuropathy Market Vendors
3.2. Strategies Adopted by Peripheral Neuropathy Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. Peripheral Neuropathy Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global Peripheral Neuropathy Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
- 5.3.1. Pharmacological Therapies
  - 5.3.1.1. Pain Relievers
    - 5.3.1.1.1. Tramadol
    - 5.3.1.1.2. Oxycodone
    - 5.3.1.1.3. Cylcooxgenase Inhibitors
    - 5.3.1.1.4. Corticosteroid
  - 5.3.1.2. Anti-seizure medicationsction
    - 5.3.1.2.1. Gabapentin
    - 5.3.1.2.2. Pregabalin
  - 5.3.1.3. Antidepressants
    - 5.3.1.3.1. Amitriptyline
    - 5.3.1.3.2. Doxepin
    - 5.3.1.3.3. Nortriptyline
    - 5.3.1.3.4. Duloxetine
    - 5.3.1.3.5. Venlafaxine
  - 5.3.1.4. Non-Pharmacological Therapies
    - 5.3.1.4.1. Transcutaneous electrical nerve stimulation
    - 5.3.1.4.2. Plasma exchange and intravenous immune globulin
    - 5.3.1.4.3. Others(Physical Therapy and Surgery)

6. North America Peripheral Neuropathy Market, 2020-2030, USD (Million)

6.1. Market Overview
6.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
6.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
- 6.3.1.North America
  - 6.3.1.1. U.S.
    - 6.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 6.3.1.2. Canada
    - 6.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 6.3.1.3. Rest of North America
    - 6.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

7. UK and European Union Peripheral Neuropathy Market, 2020-2030, USD (Million)

7.1. Market Overview
7.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
7.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
- 7.3.1.UK and European Union
  - 7.3.1.1. UK
    - 7.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 7.3.1.2. Germany
    - 7.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 7.3.1.3. Spain
    - 7.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 7.3.1.4. Italy
    - 7.3.1.4.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 7.3.1.5. France
    - 7.3.1.5.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 7.3.1.6. Rest of Europe
    - 7.3.1.6.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

8. Asia Pacific Peripheral Neuropathy Market, 2020-2030, USD (Million)

8.1. Market Overview
8.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
8.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
- 8.3.1.Asia Pacific
  - 8.3.1.1. China
    - 8.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 8.3.1.2. Japan
    - 8.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 8.3.1.3. India
    - 8.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 8.3.1.4. Australia
    - 8.3.1.4.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 8.3.1.5. South Korea
    - 8.3.1.5.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 8.3.1.6. Rest of Asia Pacific
    - 8.3.1.6.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

9. Latin America Peripheral Neuropathy Market, 2020-2030, USD (Million)

9.1. Market Overview
9.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
9.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
- 9.3.1.Latin America
  - 9.3.1.1. Brazil
    - 9.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 9.3.1.2. Mexico
    - 9.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 9.3.1.3. Rest of Latin America
    - 9.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

10. Middle East and Africa Peripheral Neuropathy Market, 2020-2030, USD (Million)

10.1. Market Overview
10.2. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
10.3.Peripheral Neuropathy Market: By Region, 2020-2030, USD (Million)
- 10.3.1.Middle East and Africa
  - 10.3.1.1. GCC
    - 10.3.1.1.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 10.3.1.2. Africa
    - 10.3.1.2.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)
  - 10.3.1.3. Rest of Middle East and Africa
    - 10.3.1.3.1. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

11. Company Profile

11.1. Abbott Laboratories
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Initiatives
11.2. Bristol Myers Squibb
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Initiatives
11.3. Cipla Limited
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Initiatives
11.4. Eli Lilly and Company
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Initiatives
11.5. GlaxoSmithKline plc.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Initiatives
11.6. Lupin Limited
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Initiatives
11.7. Merck and Co. Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Initiatives
11.8. Novartis
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Initiatives
11.9. Pfizer Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Initiatives
11.10. Dr. Reddy's Laboratories
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Initiatives

末梢神経障害の世界市場：成長、将来の見通し、競合分析（2022年～2030年）

Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

目次

第1章序文

第2章エグゼクティブサマリー

第3章末梢神経障害市場：競合分析

第4章末梢神経障害市場：マクロ分析と市場力学

第5章末梢神経障害市場：治療タイプ別（2020年～2030年）

第6章北米の末梢神経障害市場（2020年～2030年）

第7章英国・EUの末梢神経障害市場（2020年～2030年）

第8章アジア太平洋の末梢神経障害市場（2020年～2030年）

第9章ラテンアメリカの末梢神経障害市場（2020年～2030年）

第10章中東・アフリカの末梢神経障害市場（2020年～2030年）

第11章企業プロファイル

List of Tables

List of Figures

Table of Contents

1. Preface

2. Executive Summary

3. Peripheral Neuropathy Market: Competitive Analysis

4. Peripheral Neuropathy Market: Macro Analysis & Market Dynamics

5. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

6. North America Peripheral Neuropathy Market, 2020-2030, USD (Million)

7. UK and European Union Peripheral Neuropathy Market, 2020-2030, USD (Million)

8. Asia Pacific Peripheral Neuropathy Market, 2020-2030, USD (Million)

9. Latin America Peripheral Neuropathy Market, 2020-2030, USD (Million)

10. Middle East and Africa Peripheral Neuropathy Market, 2020-2030, USD (Million)

11. Company Profile

末梢神経障害の世界市場：成長、将来の見通し、競合分析（2022年～2030年）

Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 末梢神経障害市場：競合分析

第4章 末梢神経障害市場：マクロ分析と市場力学

第5章 末梢神経障害市場：治療タイプ別（2020年～2030年）

第6章 北米の末梢神経障害市場（2020年～2030年）

第7章 英国・EUの末梢神経障害市場（2020年～2030年）

第8章 アジア太平洋の末梢神経障害市場（2020年～2030年）

第9章 ラテンアメリカの末梢神経障害市場（2020年～2030年）

第10章 中東・アフリカの末梢神経障害市場（2020年～2030年）

第11章 企業プロファイル

List of Tables

List of Figures

Table of Contents

1. Preface

2. Executive Summary

3. Peripheral Neuropathy Market: Competitive Analysis

4. Peripheral Neuropathy Market: Macro Analysis & Market Dynamics

5. Peripheral Neuropathy Market: By Treatment Type, 2020-2030, USD (Million)

6. North America Peripheral Neuropathy Market, 2020-2030, USD (Million)

7. UK and European Union Peripheral Neuropathy Market, 2020-2030, USD (Million)

8. Asia Pacific Peripheral Neuropathy Market, 2020-2030, USD (Million)

9. Latin America Peripheral Neuropathy Market, 2020-2030, USD (Million)

10. Middle East and Africa Peripheral Neuropathy Market, 2020-2030, USD (Million)

11. Company Profile

第1章序文

第2章エグゼクティブサマリー

第3章末梢神経障害市場：競合分析

第4章末梢神経障害市場：マクロ分析と市場力学

第5章末梢神経障害市場：治療タイプ別（2020年～2030年）

第6章北米の末梢神経障害市場（2020年～2030年）

第7章英国・EUの末梢神経障害市場（2020年～2030年）

第8章アジア太平洋の末梢神経障害市場（2020年～2030年）

第9章ラテンアメリカの末梢神経障害市場（2020年～2030年）

第10章中東・アフリカの末梢神経障害市場（2020年～2030年）

第11章企業プロファイル